Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).


NDAQ:SYRS - Post by User

Syros Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by MikeTesteron Aug 02, 2024 10:55am
13 Views
Post# 36160803

Syros (NASDAQ:SYRS) Poised for Potential Breakthrough in Hem

Syros (NASDAQ:SYRS) Poised for Potential Breakthrough in Hemhttps://beyondspx.com/2024/07/31/syros-nasdaqsyrs-poised-for-potential-breakthrough-in-hematologic-malignancies/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities